{
    "id": 25635,
    "fullName": "MET M1149T",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MET M1149T (corresponds to M1131T in the canonical isoform) lies within the protein kinase domain of the Met protein (UniProt.org). M1149T results in constitutive Met autophosphorylation and promotes tumor formation in animal models, but is not transforming in cell culture (PMID: 9326629).",
            "references": [
                {
                    "id": 2199,
                    "pubMedId": 9326629,
                    "title": "Activating mutations for the met tyrosine kinase receptor in human cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9326629"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "M1149T",
    "createDate": "10/25/2016",
    "updateDate": "05/12/2018",
    "referenceTranscriptCoordinates": {
        "id": 144792,
        "transcript": "NM_001127500",
        "gDna": "chr7:g.116778827T>C",
        "cDna": "c.3446T>C",
        "protein": "p.M1149T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12552,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, a patient with papillary renal cell carcinoma harboring MET M1149T demonstrated stable disease when treated with Xalkori (crizotinib) (PMID: 29149761; NCT01524926).",
            "molecularProfile": {
                "id": 26652,
                "profileName": "MET M1149T"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10419,
                    "pubMedId": 29149761,
                    "title": "Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29149761"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26652,
            "profileName": "MET M1149T",
            "profileTreatmentApproaches": [
                {
                    "id": 10737,
                    "name": "MET Inhibitor",
                    "profileName": "MET M1149T"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144792,
            "transcript": "NM_001127500",
            "gDna": "chr7:g.116778827T>C",
            "cDna": "c.3446T>C",
            "protein": "p.M1149T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}